HK Stock Movement | UNITED LAB (03933) Rises Over 4% Before Noon as New Diabetes Drug Gains Attention; Semaglutide Injection Expected to Launch Next Year

Stock News11-25

UNITED LAB (03933) surged more than 4% before noon, with shares up 4.08% to HK$59.95 by the time of writing, recording a turnover of HK$31.28 million.

The company recently highlighted its diabetes product portfolio at the First Chronic Disease Prevention and Management Platform Construction Conference for Hypertension, Hyperlipidemia, and Hyperglycemia (Three-High Chronic Diseases), held in Beihai, Guangxi, on November 21–22. Among the showcased products were the newly launched liraglutide injection "UNI-LIRA®" and the upcoming semaglutide injection "UNI-SEMA®," expected to hit the market next year. These developments mark significant progress for UNITED LAB in the GLP-1-targeted therapy sector.

Notably, the company's subsidiary, United Biotech, previously entered into an exclusive licensing agreement with Novo Nordisk for UBT251. This collaboration not only validates UBT251's global market potential but also accelerates its worldwide development by leveraging Novo Nordisk's resources. The deal represents a key milestone in UNITED LAB's innovation-driven transformation, aligning its GLP-1 pipeline with international standards and expanding access to nearly 80 countries and regions, thereby enhancing the global influence of domestically developed GLP-1 therapies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179046124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 11:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179046124","market":"nz","top_or_hot":-1,"title":"HK Stock Movement | UNITED LAB (03933) Rises Over 4% Before Noon as New Diabetes Drug Gains Attention; Semaglutide Injection Expected to Launch Next Year","media":"Stock News","content":"<p>UNITED LAB (03933) surged more than 4% before noon, with shares up 4.08% to HK$59.95 by the time of writing, recording a turnover of HK$31.28 million.</p>\n<p>The company recently highlighted its diabetes product portfolio at the First Chronic Disease Prevention and Management Platform Construction Conference for Hypertension, Hyperlipidemia, and Hyperglycemia (Three-High Chronic Diseases), held in Beihai, Guangxi, on November 21–22. Among the showcased products were the newly launched liraglutide injection \"UNI-LIRA®\" and the upcoming semaglutide injection \"UNI-SEMA®,\" expected to hit the market next year. These developments mark significant progress for UNITED LAB in the GLP-1-targeted therapy sector.</p>\n<p>Notably, the company's subsidiary, United Biotech, previously entered into an exclusive licensing agreement with Novo Nordisk for UBT251. This collaboration not only validates UBT251's global market potential but also accelerates its worldwide development by leveraging Novo Nordisk's resources. The deal represents a key milestone in UNITED LAB's innovation-driven transformation, aligning its GLP-1 pipeline with international standards and expanding access to nearly 80 countries and regions, thereby enhancing the global influence of domestically developed GLP-1 therapies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | UNITED LAB (03933) Rises Over 4% Before Noon as New Diabetes Drug Gains Attention; Semaglutide Injection Expected to Launch Next Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | UNITED LAB (03933) Rises Over 4% Before Noon as New Diabetes Drug Gains Attention; Semaglutide Injection Expected to Launch Next Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-25 11:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UNITED LAB (03933) surged more than 4% before noon, with shares up 4.08% to HK$59.95 by the time of writing, recording a turnover of HK$31.28 million.</p>\n<p>The company recently highlighted its diabetes product portfolio at the First Chronic Disease Prevention and Management Platform Construction Conference for Hypertension, Hyperlipidemia, and Hyperglycemia (Three-High Chronic Diseases), held in Beihai, Guangxi, on November 21–22. Among the showcased products were the newly launched liraglutide injection \"UNI-LIRA®\" and the upcoming semaglutide injection \"UNI-SEMA®,\" expected to hit the market next year. These developments mark significant progress for UNITED LAB in the GLP-1-targeted therapy sector.</p>\n<p>Notably, the company's subsidiary, United Biotech, previously entered into an exclusive licensing agreement with Novo Nordisk for UBT251. This collaboration not only validates UBT251's global market potential but also accelerates its worldwide development by leveraging Novo Nordisk's resources. The deal represents a key milestone in UNITED LAB's innovation-driven transformation, aligning its GLP-1 pipeline with international standards and expanding access to nearly 80 countries and regions, thereby enhancing the global influence of domestically developed GLP-1 therapies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1179046124","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179046124","pubTimestamp":1764042502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UNITED LAB (03933) surged more than 4% before noon, with shares up 4.08% to HK$59.95 by the time of writing, recording a turnover of HK$31.28 million. The company recently highlighted its diabetes...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","03933":"联邦制药"},"translate_title":"港股动向|联邦制药(03933)午盘前涨超4%糖尿病新药获关注；司美格鲁肽注射液有望明年上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (03933) surged more than 4% before noon, with shares up 4.08% to HK$59.95 by the time of writing, recording a turnover of HK$31.28 million.\nThe company recently highlighted its diabetes product portfolio at the First Chronic Disease Prevention and Management Platform Construction Conference for Hypertension, Hyperlipidemia, and Hyperglycemia (Three-High Chronic Diseases), held in Beihai, Guangxi, on November 21–22. Among the showcased products were the newly launched liraglutide injection \"UNI-LIRA®\" and the upcoming semaglutide injection \"UNI-SEMA®,\" expected to hit the market next year. These developments mark significant progress for UNITED LAB in the GLP-1-targeted therapy sector.\nNotably, the company's subsidiary, United Biotech, previously entered into an exclusive licensing agreement with Novo Nordisk for UBT251. This collaboration not only validates UBT251's global market potential but also accelerates its worldwide development by leveraging Novo Nordisk's resources. The deal represents a key milestone in UNITED LAB's innovation-driven transformation, aligning its GLP-1 pipeline with international standards and expanding access to nearly 80 countries and regions, thereby enhancing the global influence of domestically developed GLP-1 therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179046124","isCrawlerRequest":true}